Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices
  • Print
  • Share
  • E-mail
-

GRN No. 1200

β-lactoglobulin produced by Komagataella phaffii strain VIPLA

Intended Use: Intended for use as a source of protein in meal replacements, high protein powdered nutritional beverages, high protein ready-to-drink nutritional beverages, nutritional bars, milk products and milk substitutes, yogurt and yogurt substitutes, cheese and cheese substitutes, frozen milk-based desserts, desserts and mousses, confections, coatings and fillings, bakery mixes, and meat, fish, and egg substitutes at levels up to 50% by weight.
Basis: Scientific procedures
Notifier: Vivici B.V.
Notifier Address: Alexander Fleminglaan 1
2613 AX Delft
Netherlands
GRAS Notice (releasable information): GRN 1200 with amendments (in PDF) (7.2 MB)
Date of closure: Feb 28, 2025
FDA's Letter: FDA has no questions (in PDF) (289 kB)
-
-